What workup should be pursued for a patient with unexplained allergic reactions and anaphylaxis, negative allergy testing and no markers for mast cell activation syndrome, who also exhibits features suggestive of Ehlers‑Danlos syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Workup for Unexplained Anaphylaxis with Ehlers-Danlos Features

Despite negative initial testing, you should pursue serum tryptase levels both at baseline and during symptomatic episodes (1-4 hours after reactions), as MCAS can still be present even when standard allergy panels are negative, and this combination of hEDS-type features with recurrent anaphylaxis strongly suggests underlying mast cell dysfunction.

Diagnostic Algorithm

Step 1: Confirm Mast Cell Activation Syndrome (MCAS)

The most recent guidelines 1 provide clear diagnostic criteria for MCAS in patients with hEDS features:

  • Obtain baseline serum tryptase when the patient is asymptomatic
  • Repeat tryptase 1-4 hours after the next symptomatic episode
  • Diagnostic threshold: An increase of ≥20% above baseline PLUS ≥2 ng/mL confirms mast cell activation 1

Critical pitfall: The statement "no marker for MCAS" likely refers to a single baseline tryptase or testing done at the wrong time. MCAS diagnosis requires paired measurements during both baseline and symptomatic periods 1. A normal baseline tryptase does NOT exclude MCAS—the diagnosis depends on the dynamic change during episodes.

Step 2: Evaluate for Clonal Mast Cell Disorders

If baseline tryptase is elevated (>11.4 ng/mL), consider underlying clonal disease 2:

  • Bone marrow examination to evaluate for systemic mastocytosis or monoclonal mast cell activation syndrome
  • Research shows 47% of patients with unexplained anaphylaxis have clonal mast cell disorders 2
  • Patients with cardiovascular symptoms (syncope) and elevated baseline tryptase are particularly high-risk 2

Step 3: Assess for Associated Conditions

The hEDS-MCAS connection is well-established 1, 3. Evaluate for:

Postural Orthostatic Tachycardia Syndrome (POTS):

  • Measure postural vital signs (heart rate increase ≥30 bpm within 10 minutes of standing)
  • If positive, refer for autonomic function testing (tilt table, sudomotor testing)
  • Consider autoantibody testing if POTS confirmed 1

Small fiber neuropathy and autonomic dysfunction commonly coexist with MCAS and contribute to symptoms 4

Step 4: Additional Diagnostic Considerations

While less specific, consider:

  • Endoscopic biopsies with CD-117 immunohistochemical staining (duodenum or ileum) if GI symptoms present—though consensus on mast cell count thresholds remains controversial 1
  • Hereditary alpha-tryptasemia testing, which can occur with anaphylaxis and MCAS 5
  • Rule out other mimics: neuroendocrine tumors, vasovagal syncope 6

Key Clinical Insights

The hEDS-MCAS phenotype overlap is significant: Research demonstrates pathophysiological links through fibroblast-mast cell interactions in the extracellular matrix 3, and recent 2025 evidence shows distinctive ECM fragmentation patterns in hEDS/HSD plasma 7. The clinical presentation of MCAS frequently meets diagnostic criteria for anaphylaxis 5, explaining your patient's recurrent episodes.

Why standard allergy testing is negative: MCAS can be IgE-independent 8. The anaphylaxis results from aberrant mast cell degranulation triggered by non-allergic mechanisms, which is why traditional allergen panels fail to identify triggers 9, 6.

Referral Strategy

Once MCAS is supported by clinical and laboratory findings, refer to:

  • Allergy specialist or mast cell disease research center for comprehensive evaluation 1
  • Consider genetics evaluation for formal hEDS diagnosis using 2017 criteria

Management Considerations While Awaiting Workup

  • Ensure patient has epinephrine auto-injectors (anaphylaxis criteria from 9 apply regardless of trigger identification)
  • Consider trial of H1/H2 antihistamines and mast cell stabilizers (cromolyn sodium) 10
  • Leukotriene receptor antagonists (montelukast) may provide benefit 10

The bottom line: Your patient likely has MCAS associated with hEDS/HSD, but the diagnosis was missed due to incomplete or improperly timed testing. The workup must include paired tryptase measurements during symptomatic episodes, not just baseline values.

References

Research

The presence of mast cell clonality in patients with unexplained anaphylaxis.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2014

Research

Mast cell activation syndrome: is anaphylaxis part of the phenotype? A systematic review.

Current opinion in allergy and clinical immunology, 2021

Research

Idiopathic Anaphylaxis.

The journal of allergy and clinical immunology. In practice, 2025

Research

Mast cell activation syndromes presenting as anaphylaxis.

Immunology and allergy clinics of North America, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.